Yes, Restoril (temazepam) can be addictive. It belongs to the benzodiazepine class of drugs, all of which carry a recognized risk of physical dependence and misuse. The FDA labels Restoril as safe and effective only for short-term use, generally 7 to 10 days, and notes that its safety beyond 2 weeks has not been established. The longer you take it and the higher the dose, the greater the risk of becoming dependent.
How Restoril Creates Dependence
Restoril works by boosting the activity of GABA, the brain’s main calming chemical. GABA opens chloride channels on nerve cells, making them less likely to fire. Restoril doesn’t activate these receptors directly. Instead, it latches onto a nearby site and amplifies whatever GABA is already doing, essentially turning up the volume on your brain’s natural braking system.
This process has a stronger quieting effect on certain inhibitory neurons in a reward-related area deep in the brain. When those inhibitory neurons are suppressed, dopamine neurons are freed up and become more active. That dopamine surge is a hallmark of how addictive substances work: it creates a rewarding feeling that the brain learns to seek out again. Over time, repeated exposure also reshapes the connections between nerve cells in that reward circuit, laying down what researchers describe as a “first trace” of drug exposure, a change shared by all drugs with addictive potential.
With continued use, the brain adjusts to the constant presence of the drug. You need more of it to feel the same sedating effect (tolerance), and without it, the nervous system rebounds into a state of overexcitement (withdrawal). That cycle of tolerance and withdrawal is the core of physical dependence.
How Quickly Dependence Develops
There is no single cutoff that applies to everyone, but the FDA’s prescribing label draws a clear line: Restoril is intended for 7 to 10 days of use, and its safety beyond 2 weeks is unknown. The risk of dependence rises with both duration and dose. People who take higher amounts or use the drug for longer stretches face the greatest risk of withdrawal symptoms when they stop.
Some people develop physical dependence within just a few weeks of nightly use. Others may take it intermittently for months without obvious problems. Individual factors like genetics, history of substance use, and whether you’re also taking other sedating medications all influence how quickly your brain adapts to the drug.
Dependence vs. Addiction
Physical dependence and addiction overlap, but they aren’t the same thing. Dependence means your body has adjusted to the drug and will react if it’s removed. Addiction involves a broader pattern of harmful behavior around the drug.
Clinicians diagnose a sedative use disorder when a person meets at least two of eleven criteria within a 12-month period. Those criteria fall into four categories: impaired control (taking more than intended, failed attempts to cut back, cravings), social impairment (neglecting responsibilities, relationship conflict), risky use (driving while impaired, continuing despite health problems), and physical signs (tolerance and withdrawal). Meeting two or three criteria points to a mild disorder. Six or more indicates a severe one.
Someone who takes Restoril exactly as prescribed for a few weeks and then struggles to stop may be physically dependent without meeting the full criteria for addiction. But that dependence can easily slide into addiction if the person starts taking extra doses to chase the sedating effect or obtains the drug outside of a prescription.
Who Is Most at Risk
Roughly 4.6 million Americans aged 12 or older misused a prescription tranquilizer or sedative in 2024, according to the most recent national drug use survey. Adults 26 and older accounted for the largest share, about 3.8 million people. Among young adults 18 to 25, misuse actually declined between 2021 and 2024, dropping from about 916,000 to 571,000.
Risk factors for developing a problem with Restoril specifically include a personal or family history of substance use disorders, a history of mental health conditions like anxiety or depression, and concurrent use of other substances that depress the central nervous system, particularly alcohol and opioids. Combining Restoril with these substances dramatically increases the risk of dangerous respiratory depression, where breathing slows or stops entirely.
What Withdrawal Feels Like
Stopping Restoril abruptly after regular use can trigger a range of withdrawal symptoms. Mild to moderate symptoms include rebound insomnia (often worse than the sleep problems the drug was originally prescribed for), anxiety, irritability, muscle tension, and restlessness. More severe withdrawal can involve tremors, sweating, nausea, and in rare cases, seizures or psychosis.
The severity depends on how long you’ve been taking the drug, the dose, and how quickly you stop. Withdrawal from a short-acting benzodiazepine like Restoril tends to begin within one to two days after the last dose, peak around the end of the first week, and gradually improve over the following weeks. For people who have used benzodiazepines for months or years, some symptoms like sleep disruption and anxiety can linger for much longer.
How Tapering Works
Because of the seizure risk, stopping Restoril cold turkey is not recommended after more than a brief period of use. A gradual taper is the standard approach. The American Society of Addiction Medicine recommends starting with a small reduction, typically 5 to 10 percent of the current dose, then monitoring how you respond before making the next cut.
The pace varies widely from person to person. Some people tolerate reductions every one to two weeks. Others need to hold at a given dose for several weeks before their body adjusts enough to drop again. For people who have been on benzodiazepines for a long time, a full taper can take more than a year. Symptoms during the process should guide the speed of each reduction. If withdrawal symptoms become too uncomfortable, the plan can be paused or the steps made smaller.
Restoril’s Legal Classification
The U.S. Drug Enforcement Administration classifies temazepam as a Schedule IV controlled substance. That places it in the same category as other benzodiazepines like lorazepam and alprazolam. Schedule IV means the federal government recognizes a real but lower potential for abuse compared to drugs in Schedules I through III. Prescriptions are regulated, and refills are limited.
The scheduling reflects a middle ground: Restoril is less prone to misuse than, say, oxycodone (Schedule II), but its addictive potential is well-documented enough to warrant controlled access. The FDA’s prescribing label now carries explicit warnings about the risks of abuse, misuse, and addiction, alongside the risk of life-threatening withdrawal if the drug is stopped too quickly.